

## Original article

# Rationale and design of DiPPI: A randomized controlled trial to evaluate the safety and effectiveness of progressive hemodialysis in incident patients<sup>☆</sup>

Miguel A. Suárez<sup>a,\*</sup>, Emilio García-Cabrera<sup>b</sup>, Antonio Gascón<sup>c</sup>, Francisca López<sup>d</sup>, Eduardo Torregrosa<sup>e</sup>, Giannina E. García<sup>f</sup>, Jorge Huertas<sup>g</sup>, José C. de la Flor<sup>h</sup>, Suleyka Puello<sup>i</sup>, Jonathan Gómez-Raja<sup>j</sup>, Jesús Grande<sup>k</sup>, José L. Lerma<sup>l</sup>, Carlos Corradino<sup>m</sup>, Manuel Ramos<sup>n</sup>, Jesús Martín<sup>o</sup>, Carlo Basile<sup>p</sup>, Francesco G. Casino<sup>p,q</sup>, Javier Deira<sup>r</sup>

<sup>a</sup> Unidad de Nefrología, Hospital Virgen del Puerto, Plasencia, Spain

<sup>b</sup> Delos Clinical Research Organization, Sevilla, Spain

<sup>c</sup> Unidad de Nefrología, Hospital Obispo Polanco, Teruel, Spain

<sup>d</sup> Unidad de Nefrología, Hospital Costa del Sol, Marbella, Spain

<sup>e</sup> Unidad de Nefrología, Hospital de Manises, Valencia, Spain

<sup>f</sup> Unidad de Nefrología, Hospital Arquitecto Marcide, Ferrol, Spain

<sup>g</sup> Unidad de Nefrología, Hospital de Especialidades de las Fuerzas Armadas, Quito, Ecuador

<sup>h</sup> Unidad de Nefrología, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain

<sup>i</sup> Unidad de Nefrología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain

<sup>j</sup> FundeSalud, Mérida, Spain

<sup>k</sup> Unidad de Nefrología, Hospital Virgen de la Concha, Zamora, Spain

<sup>l</sup> Unidad de Nefrología, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain

<sup>m</sup> Centro de Diálisis Ciudad de Lobos, Buenos Aires, Argentina

<sup>n</sup> Unidad de Nefrología, Hospital de Jerez, Jerez de la Frontera, Spain

<sup>o</sup> Unidad de Nefrología, Hospital Nuestra Sra. de Sonsoles, Ávila, Spain

<sup>p</sup> Clinical Research Branch, Division of Nephrology, Miulli General Hospital, Acquaviva delle Fonti, Italy

<sup>q</sup> Dialysis Centre SM2, Potenza, Italy

<sup>r</sup> Unidad de Nefrología, Hospital San Pedro de Alcántara, Cáceres, Spain

## ARTICLE INFO

## Article history:

Received 26 September 2017

Accepted 3 July 2018

Available online 5 December 2018

## ABSTRACT

**Introduction:** Progressive haemodialysis (HD) is a starting regime for renal replacement therapy (RRT) adapted to each patient's necessities. It is mainly conditioned by the residual renal function (RRF). The frequency of sessions with which patients start HD (one or two sessions per week), is lower than that for conventional HD (three times per week). Such frequency is increased (from one to two sessions, and from two to three sessions) as the RRF declines.

DOI of original article:

<https://doi.org/10.1016/j.nefro.2018.07.010>.

<sup>\*</sup> Please cite this article as: Suárez MA, García-Cabrera E, Gascón A, López F, Torregrosae E, García GE, et al. Justificación y diseño de DiPPI: un ensayo controlado aleatorizado para evaluar la seguridad y la efectividad de la hemodiálisis progresiva en pacientes incidentes. *Nefrología*. 2018;38:630-638.

<sup>\*</sup> Corresponding author.

E-mail address: [Santisteban79@gmail.com](mailto:Santisteban79@gmail.com) (M.A. Suárez).

2013-2514/© 2018 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:**

Chronic renal failure  
Incremental haemodialysis  
Progressive haemodialysis  
Randomized clinical trial

**Methodology/Design:** IHDIP is a multicentre randomized experimental open trial. It is randomized in a 1:1 ratio and controlled through usual clinical practice, with a low intervention level and non-commercial. It includes 152 patients older than 18 years with chronic renal disease stage 5 and start HD as RRT, with an RRF of  $\geq 4$  ml/min/1.73 m<sup>2</sup>, measured by renal clearance of urea (KrU). The intervention group includes 76 patients who will start with one session of HD per week (progressive HD). The control group includes 76 patients who will start with three sessions per week (conventional HD). The primary purpose is assessing the survival rate, while the secondary purposes are the morbidity rate (hospital admissions), the clinical parameters, the quality of life and the efficiency.

**Discussion:** This study will enable us to know, with the highest level of scientific evidence, the number of sessions a patient should receive when starting the HD treatment, depending on his/her RRF.

**Trial registration:** Registered at the U.S. National Institutes of Health, ClinicalTrials.gov under the number NCT03239808.

© 2018 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Justificación y diseño de DiPPI: un ensayo controlado aleatorizado para evaluar la seguridad y la efectividad de la hemodiálisis progresiva en pacientes incidentes

### R E S U M E N

**Palabras clave:**

Insuficiencia renal crónica  
Hemodiálisis incremental  
Hemodiálisis progresiva  
Estudio aleatorizado controlado

**Introducción:** La hemodiálisis (HD) progresiva es una modalidad de inicio del tratamiento renal sustitutivo adaptada a las necesidades individuales de cada paciente. Está condicionada fundamentalmente por la función renal residual (FRR). En ella, la frecuencia de sesiones con las que el paciente inicia HD (una o 2 sesiones por semana) es menor que en la HD convencional (3 por semana). Dicha frecuencia aumenta (de una a 2, y de 2 a 3) con el declinar de la FRR.

**Metodología/diseño:** DiPPI es un estudio abierto, multicéntrico, experimental, aleatorizado 1:1 y controlado con procedimiento de práctica clínica habitual, de bajo nivel de intervención y no comercial. Incluye 152 pacientes mayores de 18 años, con enfermedad renal crónica estadio 5, que inician HD como tratamiento renal sustitutivo; y la FRR, medida por aclaramiento renal de urea (KrU) es  $\geq 4$  ml/min/1,73 m<sup>2</sup>. El estudio se basa en un grupo de intervención con 76 pacientes que iniciarán HD con una sola sesión por semana (modalidad progresiva) y un grupo control con 76 pacientes que comenzarán con 3 sesiones por semana. El objetivo primario es evaluar la supervivencia y los objetivos secundarios son la morbilidad (hospitalizaciones), los parámetros clínicos habituales, la calidad de vida y la eficiencia.

**Discusión:** Este estudio permitirá conocer, con la máxima evidencia científica, cuántas sesiones debe recibir un paciente al inicio del tratamiento con HD, dependiendo de su FRR.

**Registro:** Registrado en U.S. National Institutes of Health, ClinicalTrials.gov con número NCT03239808.

© 2018 Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Conventional hemodialysis (HD) of 3 days per week for 3–5 h, as outpatient in a health center, is the most widely used modality of renal replacement therapy (RRT)<sup>1</sup>; however, it has an unacceptably high mortality (10–20% per year).<sup>2</sup> In incident patients, the transition to HD during the first year entails even worse results, with the intervention of factors outside the RRT.<sup>3</sup> To improve these results, new techniques and

modalities based on more dose of HD and/or more sessions<sup>2</sup> have been proposed. Nonetheless, recently published randomized controlled trials have shown controversial results in relation to the clinical benefit,<sup>4,5</sup> together with a higher rate of vascular access complications,<sup>6</sup> and a lower preservation of residual kidney function (RKF).<sup>7</sup>

The 2015 guidelines of the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (KDOQI)<sup>1</sup> allow to reduce the weekly dose of dialysis in patients with urea renal clearance (KrU) greater than 3 ml/min/1.73 m<sup>2</sup>. In these cases,

the dialysis clearance (Kd) obtained with 2 sessions/week is added to renal clearance (Kr), achieving an adequate dose of dialysis.<sup>8,9</sup> It is surprising that few centers follow this recommendation when more than 50% of patients initiate HD with a KrU > 3 ml/min.<sup>10</sup>

Authors such as Kalantar-Zadeh et al.<sup>10,11</sup> in USA or Teruel et al.,<sup>12</sup> in Spain, have published their experience with 2 sessions of HD per week in incident patients. With this modality they manage to preserve RKF and survival rates similar to those obtained with conventional HD. This could be explained by the fact that Kr had a clinical weight greater than Kd,<sup>8</sup> since RKF, in addition to maintaining the homeostasis of the internal environment, contributes to the production of vitamin D and erythropoietin,<sup>13,14</sup> and to the purification of protein bound uremic toxins which are poorly dialyzed.<sup>14,15</sup> We can state that the correlation between RKF and survival is strong and consistent, as well as playing a crucial role in achieving adequate dialysis.<sup>1,9,16</sup>

Currently, the number of sessions that a patient must have at the initiation of HD is a matter of debate.<sup>8,17-19</sup> Progressive HD is an option for initiation of HD which is adapted to the RKF, where the frequency of HD sessions increases as the volume of daily diuresis declines.<sup>8,17-19</sup>

The study "Evaluation of the Safety and Effectiveness of Progressive Hemodialysis in Incident Patients" (DiPPI)<sup>20</sup> aims to determine whether initiating HD with one session per week reduces mortality in incident patients and has an effect on morbidity (hospitalizations), clinical parameters, quality of life and efficiency compared with those patients who initiate RRT with conventional HD.

## Method and study design

### Design

Prospective, multicenter, open, randomized and controlled clinical trial with the usual clinical practice, based on starting HD with 3 sessions per week (control group).

### Intervention

It consists in reducing the frequency or number of weekly sessions at the initiation of HD. The experimental group will start with a session/week to progress to 2 and then to 3 sessions/week according to progression criteria.

DiPPI does not use drugs or placebos, and the complementary diagnostic or follow-up procedures do not entail risk for the safety of the subjects, being similar to those of the usual clinical practice. Therefore, it is considered a "low level intervention clinical trial". It is also a "non-commercial clinical research", as it has been designed directly by the promoters and principal investigators, without any input from the industry.

### Participants

Hospital units and outpatient HD centers from different geographical areas. It will include only incident patients. Patients

admitted for intercurrent problems will remain in the assigned group of the study and will be evaluated according to their randomization.

### Inclusion criteria

- Over 18 years of age with chronic kidney disease (CKD) stage 5 who have chosen HD as a the modality of treatment.
- RKF measured by KrU<sup>21</sup>  $\geq$  4 ml/min/1.73 m<sup>2</sup>. In general it is recommended not to start HD with a KrU > 7.
- Informed consent signed.

### Exclusion criteria

- Urgent or non-scheduled initiation of HD. It is assumed that this situation does not allow the collection of urine for 24 h before the first session, or that had not collected 24 h urine in the previous 30 days.
- Patients prevalent in other modalities of RRT.
- Associated diseases: active neoplasia, cardiorenal or hepatorenal syndrome, active inflammatory disease, cardiovascular disease defined as HYHA class IV heart failure, unstable angina, or ischemic heart disease with admission in the previous 3 months.

### Progression criteria

Patients in the experimental group will increase from 1-2 weekly sessions, if they meet any of the following criteria:

- Decrease in KrU<sup>21</sup> (less than 4 and more than 2.5 ml/min/1.73 m<sup>2</sup>). This decrease must be confirmed in the following analytical tests obtained the following month.
- Inter-session weight gain (weekly) that entails ultrafiltration rates higher than 13 ml/kg/h, maintained for 3 weeks.
- Clinical event that requires unscheduled sessions (more than one).

Patients with 2 sessions per week will go to conventional HD if:

- KrU<sup>21</sup> is less than 2.5 ml/min/1.73 m<sup>2</sup>, and/or standard Kt/V less than 2.1 weekly. This decrease must be confirmed in the following analytical test obtained the following month.
- Inter-session weight gain that conditions an ultrafiltration rate higher than 13 ml/kg/h, maintained during 3 sessions.
- Clinical event that requires unscheduled sessions for resolution.

### Time schedule for participants

- Recruitment period: 18 months since the inclusion of the first patient. Patients selected as candidates will be registered in the patients form (Appendix A). If they meet the eligibility criteria and sign the informed consent, they will be randomized.

- Follow-up period: 24 months. In it biochemical determinations and diagnostic tests will be performed with the periodicity that appears in the calendar of visits (Table 1). Patients in the experimental group, when they progress to 3 sessions/week, will perform the same visits as the control group. The work scheme is defined in Table 1.

Withdrawal from the study: any patient will be withdrawn from the study due to the following: recovery of the RF, kidney transplant, loss of follow-up, exit from the program and withdrawal of consent. In these cases, the follow-up visit will be carried out and no replacement will be made.

## Objective

### Primary objective

- Survival. Study period: 2 years.

### Secondary objectives

- Hospitalizations for any reason. Study period: 2 years.
- Preservation of the RKF. Study period: 2 years.
  - Reduction of glomerular filtration rate (GFR) and tubular function.
  - Average volume of diuresis and percentage of patients in anuria (volume  $\leq$  200 ml/day) in 2 consecutive measurements.
- Adequacy parameters. Study time: 3, 6, 12 months and 2 years.
  - Control of anemia. Patients with hemoglobin levels in the therapeutic range (expressed in %) and average levels of the erythropoietin resistance index (ERI in IU/kg/week).
  - Control of bone-mineral metabolism. Mean levels of calcium, phosphorus and intact parathyroid hormone and percentage of patients within therapeutic range.
  - Control of specific heart disease. Study time: 12 and 24 months. Left ventricular ejection fraction (LVEF). Percentage of patients with a left ventricular mass index (LVMI) adjusted to body surface  $\geq$  125 g/m<sup>2</sup>, or with pericardial effusion.
  - Control of Quality of life. Score obtained in the validated Kidney Disease and Quality of Life survey (KDQOL'36 SF).
  - Cost effectiveness of the intervention: expressed as an increase in cost per additional year gained, adjusted to the quality of life.

### Sample size

It was calculated to detect differences in the contrast of the null hypothesis  $H_0$ : the ratio between the medians of the survival time is not inferior to the noninferiority limit, by means of a log-rank test for 2 independent samples (of non-inferiority in a function of exponential survival). For this, it is necessary to include 152 patients in the study, with a 1:1 randomization, that is, 76 patients in each group, assuming the following parameters:

- Inclusion period of 18 months.
- Maximum duration of the follow-up period, 24 months.
- Median survival in the conventional HD group, 74 months.
- Average of the time until the censoring, 12 months.
- Non-inferiority limit of 4 months.
- Error type I 5% (significance).
- Error type II 20% (power).

### Randomization

There is a centralized single list. It has 152 randomization codes (sample size) and an additional 24 in case that more patients are included. It has 2 stratus: according to age ( $>0 < 75$  years), and according to the basal KrU ( $\geq 0 < 5.5$  ml/min/1.73 m<sup>2</sup>). This randomization is balanced every 6 participants.

The investigator responsible for each center will formally request the randomization to the clinical research office (C.R.O. Delos Clinical) through annex 1.

### Centralized prescription of the dialysis dose

Each patient will receive a "centralized prescription" of the dose. It will be based on the necessary eKt/V according to the KrU of each patient, to obtain an EKtU of 12-KrU ml/min/1.73 m<sup>2</sup> in a weekly HD and a stdKt/V of 2.3 volumes weekly for 2 times, as published by Casino and Basile.<sup>22</sup> All calculations related to the kinetic model of urea (UKM) are based on the prescription tool<sup>23</sup> and the Solute-Solver<sup>24</sup> software. The control group will receive a dose of spKt/V of 1.4 per session, neglecting the RKF.<sup>1</sup>

Note: KDOQI1 suggest a stdKt/V = 2 weekly volumes for HD programs other than 3 times per week HD. But it is not mention the schedule once a week. Therefore, we adopted the variable goal recently suggested for EKRU as a guide for the week program, which seems to be in accordance with our empirical experience.

### Variables

The data will be obtained from the patient's medical history. Researchers will fill in the electronic data collection notebook (CRDe) in the foreseen periods.

*Demographic, clinical data and tests performed.* The biochemical determinations, the diagnostic tests and their periodicity are shown in Table 1, and are usually recommended in the guidelines for these patients.

*Survival.* The follow-up will be determined in days. It will be the difference from the date of the end of follow-up and the date of the baseline visit. Events will be counted as deaths (follow-up less than 24 months) or as an end to follow-up (24 months).

*Hospitalizations:* number and days of Hospitalizations will be recorded in each patient. Reasons for admission are: infections, problems with the vascular access (performance, repair, replacement, thrombosis or bleeding), heart disease, gastrointestinal bleeding or others.

*Preservation of the RKF.* The GFR (in ml/min) will be calculated by the half-sum of the clearance of urea and creatinine,

and the tubular function by means of the fractional excretion of phosphorus, uric acid and potassium.

*Control of anemia.* Hemoglobin level (in g/dl) will be measured and doses of erythropoiesis stimulating agents (in IU) will be obtained.

*Control of bone-mineral metabolism.* Calcium, phosphorus (both in mg/dl) and intact PTH (in pg/dl) will be measured.

*Control of specific heart disease.* The LVEF (in%), the LVMI (in g/m<sup>2</sup>) and the presence of pericardial effusion will be assessed.

**Table 1 – Organization chart of study visits.**

	Variables	Selection visit	Baseline visit	1st month visit <sup>a</sup>	Third month visit	1st Year visit	End of follow-up visit
Inclusion and exclusion criteria	Point 2	X					
Informed consent	Anex 3	X					
Recording of demographic data			X				
Records of Comorbidity data	Chalson index, heart failure Cardiovascular Dis. Cerebrovascular Dis Peripheral vascular Dis. Chronic pulmonary Dis Liver disease Other		X				
Toiology of ERC	EDTA code		X				
Hospital admissions	Number of admissions Days hospitalized Cause of admission			PHD	X		X
Data referring to the technique	Numbers of sessions Effective time Vascula access Dry weight and Blood pressure Weight gain KT/Vstad			X	X		X
Residual kidney function	24 h urine volume (in ml), urea, creatinine, uric acid, in blood and urine (mg/dl). Proteinuria in g/24 h Weight, height and KrU (ml/min/1.73 m <sup>2</sup> )		X	X	X		X
Bioimpedance	Urea distribution volume (L) Lean index (LTI) and fat index (FTI) (Both in kg/m <sup>2</sup> ) State of overhydration pre and postHD (L)		X	PHD	X		X
Acid-base and electrolytic	pH, bicarbonate and potassium in blood predialysis		X	PHD	X		X
Erythropoietic parameters	Hemoglobin (Hb) and the dose of erythropoiesis stimulating agents and resistance index		X	PHD	X		X
Parameters of bone-mineral metabolism	Serum value of PTH, phosphorus, calcium and magnesium (mg/dl).		X		X		X
Parameters nutrition-inflammation	Serum value of total proteins, albumin, b2microglobulin, CRP and transferrin.		X		X		X
Ferric parameters	Serum iron (Fe), transferrin saturation index (TSAT) and serum ferritin.		X		X		X
Quality of life	Kidney Disease and Quality of Life (KDQOL'36 US Spanish)		X		X		X
Usual treatment	Drugs and doses of antihypertensives, diuretics, bicarbonate, P binders, calcimimetics, vitamin D analogs		X		X		X
Echocardiogram	Ejection fraction (% EF) of the left ventricular mass (MVI/m <sup>2</sup> )		X			X	X

In the data referring to the technique, if there are several parameters (for example TA, weight gain, etc.), the value recorded will correspond to the session in which the analytical measurements are obtained.

**Quality of life.** The items of the KDQOL'36 SF survey will be recorded.

**Cost effectiveness of the intervention.** The costs during the follow-up will be calculated in each patient. The costs will be counted as: the sessions carried out, at the rate of € 201 per session, the transport to the center at € 20 per session, and the hospital admissions at € 498 per day of admission.<sup>25</sup> These rates will not reflect the costs, nor the prices paid for each service. Nor will they be representative of all participating hospitals. However, when used as ratios, it will be possible to calculate which type of HD start is less expensive, and therefore more efficient.

**Period of time (Tp) in progressive HD.** Each patient in a progressive HD modality will be registered. Will measure the period time from the beginning of the study until progression to 2 sessions per week (Tp in one HD session/week in days). Likewise the period of time in days from the initiation of 2 HD sessions per week until conventional HD or end of the study will be measured (Tp in 2 HD sessions/week in days). The period of time (in days) since the beginning of the study to the initiation of conventional HD or end of the study will also be recorded (Tp in progressive HD in days).

## Statistical methods

### Population to analyze

All patients included in the study, regardless of their follow-up period, that is, the study population is by intention to treat.

### Intermediate analysis

All the objectives will be analyzed in all patients when they reach 12 months of follow-up. In this analysis, methodology and variables will be the same as the analysis to be performed at the end of the follow-up period (Fig. 1).

### Descriptive analysis

All variables collected at baseline visit will be evaluated. The qualitative variables will be expressed as percentages and differences will be evaluated using the Chi-square test or the Pearson statistical test if the distribution of observed frequencies is not fulfilled. The quantitative variables will be expressed as mean, median, standard deviation and interquartile range; to assess differences will use the Student's "t" or the Mann-Whitney test if the normal distribution is not met. They will have a level of significance of 5% and a power of 80% for the achievement of the objectives.

### Primary objective

**Analysis of survival.** It will be measured by a bivariate analysis or Kaplan-Meier test. The difference between the mean and median survival time, between both branches of the study, will be analyzed by log-rank test. A multivariate analysis or multivariate Cox regression will be performed to assess the real contribution of the intervention (progressive HD) and/or any variable that affects survival.

## Secondary objectives

**Analysis of hospital admissions.** In each group, the average number of admission and days admitted to the hospital will be calculated. The difference between the means will be evaluated by Student's "t" or its non-parametric Mann-Whitney alternative.

**Analysis of the RKF.** The changes in GFR, tubular function and the 24 h urine volume from baseline during the follow-up will be compared using the Wilcoxon test. The period of time maintaining the RKF (volume  $\geq$  200 ml/day) will be evaluated using the Kaplan-Meier technique. To assess the differences between the mean and the median, the log-rank test will be performed. The proportion of patients (in%) with a volume  $\leq$  200 ml/day at the end of the follow-up will be compared by Chi-square test or Pearson's statistical test (according to the distribution of observed proportions).

**Other analytical parameters.** To compare the percentage of patients with hemoglobin  $<$  10.5 g/L, or calcium, phosphorus and PTH within the therapeutic range (in each branch of the study), the Chi-square test or the Pearson test will be performed, the later will be used if the frequency distribution is not fulfilled. The differences between mean levels of the resistance index to erythropoietin, calcium, phosphorus and intact PTH will be evaluated using the Student's "t" or its nonparametric Mann-Whitney alternative.

**Functional data.** The differences in LVEF, LVMI, in the items of the quality of life questionnaire and in the calculation of the efficiency (in each branch of the study) will be evaluated using the Student's "t" test or its non-parametric alternative, the test of Mann-Whitney. To assess the difference in the existence of pericardial effusion, the Chi-square test or the Pearson test will be performed if the observed frequency distribution is not met.

## Security controls

During follow-up, and especially in the experimental group, attention will be paid to volume overload, hyperkalemia and metabolic acidosis, as advised in usual clinical practice. The monthly bioimpedance in patients in progressive HD, and quarterly in the control group, will help to calculate of dry weight and to rule out overhydration. For the control of potassium and metabolic acidosis, researchers can perform a control of both parameters in the inter-monthly period.

The trial will be carried out in accordance with its protocol,<sup>22</sup> with the guidelines of good clinical practice and with the applicable legal requirements in each country with participating centers. The confidentiality of the data will be carried out in accordance with Organic Law 15/1999 on the Protection of Personal Data and Royal Decree 1720/2007.

## Discussion

The transition from stage 5 not dependent of dialysis to the RRT is a crucial moment, both for the patient and for the nephrologist. You must choose, among others, 3 issues: when and how to start the RRT and the amount of extrarenal clearance that we must provide. Despite the absence of controlled




Fig. 1 – Timeline schedule.

studies to support it, there has been a tendency of early initiation of TRS.<sup>1</sup> Thus, in the USA, more than 50% of the patients currently start with a  $KrU > 3 \text{ ml/min/1.73 m}^2$ , without any evidence that this strategy had reduced morbidity and mortality.<sup>10</sup>

The initiation of progressive dialysis, defined as the gradual increase in dose of dialysis as RKF decreases, aims to maintain constant total solute clearance ( $Kr$  and  $Kd$ ). In peritoneal dialysis, a progressive dialysis was already proposed in its first guidelines on adequacy,<sup>26</sup> and is currently strongly implemented. Thus, in some countries 30% of patients start with one or two exchanges/day, or with 3 or 4 sessions/week of automated DP,<sup>27</sup> and this happens despite the fact that studies on incremental PD are limited, with a low number of patients, non-randomized and from a single center.<sup>27</sup>

Progressive or incremental HD has also gained some importance in recent years. It has been carried out without economic purposes and has shown encouraging results in the maintenance of RKF, and with a survival similar to conventional HD.<sup>10-13</sup> In fact, guide 3.2 of the KDOQI1 allows to reduce the weekly dose in patients with a  $KrU$  greater than  $3 \text{ ml/min/1.73 m}^2$ . In these cases, the objective is continuous clearance of 2.3 volume weekly, expressed in  $\text{stdKt/V}$  terms, or an  $\text{EKrU}$  of  $12\text{-KrU ml/min}$ , both corrected for a volume of 35 L.<sup>2,22</sup> These recommendations are based on the strong correlation between RKF and survival,<sup>9</sup> and the contribution of RKF to volume control and to the elimination of protein

bound solutes via tubular secretion.<sup>28,29</sup> It should be remembered that the protein bound solutes are poorly dialyzed with current techniques, even if frequency is increased.<sup>29,30</sup>

The studies published on incremental HD are observational, and their results should be taken with caution.<sup>10-12</sup> Presently there is not enough evidence to determine which regimen of dose or frequency, should receive incident patients in HD with RKF.

Based on previous experiences<sup>22,31</sup> and according to some authors<sup>19,21</sup> in DiPPI, we have proposed starting with a single weekly session and increasing to 2 and from 2 to 3 as the RKF declines. Although it seems daring, it is more logical to move gradually from stage 5 noD to stage 5HD. We hope to obtain the same survival and the same complication rate at 2 years. If this starting modality is confirmed to be as effective and safe, it will reduce the number of sessions in many incident patients. Thus, if one of every 4 HD patients in Spain initiate dialysis progressively, 76,000 sessions would be “avoided”, with their respective trips, and costs would decrease by more than 21 million euros per year.

The methodological design was carefully considered. In principle, an observational cohort design was chosen, controlling the selection bias by propensity score matching. This method must have enough variables to avoid bias, which implies a large control group to be able to find paired patients. But this does not eliminate the “residual confounding factors”,

a threat in any observational study. A randomized controlled study has a minimal bias and provides the highest level of evidence, although it presents notable difficulties: lower power, selection of patients that produces randomization (may not be representative of the population in HD), or imbalances between both groups in some key variable. We believe that the sample calculation and randomization by blocks have minimized these drawbacks and will allow to respond the proposed hypothesis. It is not masked due the obvious difficulty of masking the sessions.

Possibly DiPPI is as necessary as previous studies such as HEMO,<sup>32</sup> IDEAL<sup>33</sup> or those resulting from of the FHN.<sup>4–6</sup> The results of the DiPPI study will have the same importance as those mentioned. But as in the case of a non-commercial study, there is no funding for the inclusion of patients. Avoiding underdialysis is as important goal as overdialyzing, and this clinical trial will try to show whether there is a difference between progressive HD and fixed-dose HD 3 times a week in incident patients. The potential benefits and economic savings is a sufficient reason to carry out an effort by everyone. If you are interested in this topic or you value the possibility of participating in the study, we will provide you with all the necessary information.

## Abbreviations

CRDe: electronic data collection notebook; DiPPI: incremental dialysis in incident patients (acronym of the study); CKD: chronic kidney disease; LVEF: left ventricular ejection fraction; RKF: residual kidney function; HD: hemodialysis; GFR: glomerular filtration rate; LVMI: left ventricular mass index; IRE: index of resistance to erythropoietin, Kd: dialytic clearance; KDOQI: Kidney Disease Outcomes Quality Initiative; KDQOL<sup>36</sup>: Kidney Disease and Quality of Life; Kr: renal clearance; KrU: renal clearance of urea; stdKt/V: standard Kt/V; RRT: renal replacement therapy.

## Ethics committee and endorsements

Favorable evaluation of the Ethics and Research Committee of the Hospital Complex of Cáceres. Endorsed by the Ministry of Health and Social Policies of the Junta de Extremadura and by the Spanish Society of Nephrology. Sponsored by the Foundation for Training and Research of Health Professionals of Extremadura (FundeSalud), under the Ministry of Health of the Junta de Extremadura.

## Contribution of the authors

All the authors have actively contributed to the design of the study, its methodology and the writing of the manuscript.

## Funding

Currently, the project has an financial aid provided by Fundación Liberbank of 10,000 net euros, conveyed through FundeSalud.

## Conflict of interests

None of the authors stated that they had a conflict of interest.

## Acknowledgements

To doctors J.L. Teruel and F. Maduell for their inestimable collaboration in the methodology and design of the study.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.nefro.2018.11.011.

## REFERENCES

1. National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. *Am J Kidney Dis.* 2015;66:884–930.
2. Chan CT, Covic A, Craig JC, Davenport A, Kasiske BL, Kuhlmann MK, et al. Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes. *Kidney Int.* 2013;83:359–71.
3. Foley RN, Chen SC, Solid CA, Gilbertson DT, Collins AJ. Early mortality in patients starting dialysis appears to go unregistered. *Kidney Int.* 2014;86:392–8.
4. Chertow GM, Levin NW, Beck GJ, Daugirdas JT, Eggers PW, Klinger AS, et al. Frequent Hemodialysis Network (FHN) Trials Group. Long-Term effects of frequent in-center hemodialysis. *J Am Soc Nephrol.* 2016;27:1830–6.
5. Rocco MV, Daugirdas JT, Greene T, Lockridge RS, Chan C, Pierratos A, et al. Long-term effects of frequent nocturnal hemodialysis on mortality: The Frequent Hemodialysis Network (FHN) nocturnal trial. *Am J Kidney Dis.* 2015;66:459–68.
6. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, et al. Risk of vascular access complications with frequent hemodialysis. *J Am Soc Nephrol.* 2013;24:498–505, <http://dx.doi.org/10.1681/ASN.2012060595>.
7. Daugirdas JT, Greene T, Rocco MV, Kaysen GA, Depner TA, Levin NW, et al. Effect of frequent hemodialysis on residual kidney function. *Kidney Int.* 2013;83:949–58, doi:0.1038/ki.2012.457.
8. Casino FG, Basile C. The variable target model: a paradigm shift in the incremental haemodialysis prescription. *Nephrol Dial Transplant.* 2017;32:182–90.
9. Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. *J Am Soc Nephrol.* 2004;15:1061–70.
10. Obi Y, Streja E, Rhee CM, et al. Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: a cohort study. *Am J Kidney Dis.* 2016;68:256–65.
11. Zhang M, Wang M, Li H, Yu P, Yuan L, Hao C, et al. Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. *Am J Nephrol.* 2014;40:140–50, <http://dx.doi.org/10.1159/000365819>.



12. Fernández M, Teruel JL. Incremental hemodialysis schedule at the start of renal replacement therapy. *Nefrologia*. 2017;37:1-4, <http://dx.doi.org/10.1016/j.nefro.2016.08.002>.
13. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. *Nephrol Dial Transplant*. 2009;24:2502-10, <http://dx.doi.org/10.1093/ndt/gfp071>.
14. Mathew AT, Fishbane S, Obi Y, Kalantar-Zadeh K. Preservation of residual kidney function in hemodialysis patients: reviving an old concept. *Kidney Int*. 2016;90:262-71.
15. Patel N, Hu SL. Preserving residual renal function in dialysis: what we know. *Semin Dial*. 2015;28:250-8.
16. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. *Am J Kidney Dis*. 2010;56:348-58, <http://dx.doi.org/10.1053/j.ajkd.2010.03.020>.
17. Libetta C, Nissani P, Dal Canton A. Progressive hemodialysis: is it the future? *Semin Dial*. 2016;29:179-83, <http://dx.doi.org/10.1111/sdi.12455>.
18. Toth-Manikowski SM, Shafi T. Hemodialysis prescription for incident patients: twice seems nice, but is it incremental. *Am J Kidney Dis*. 2016;68:180-3.
19. Wong J, Vilar E, Davenport A, Farrington K. Incremental haemodialysis. *Nephrol Dial Transplant*. 2015;30:1639-48, <http://dx.doi.org/10.1093/ndt/gfv231>.
20. "Incremental haemodialysis in Incident Patients (IHDIP)" en la U.S. National Library of Medicine. Available from: <https://clinicaltrials.gov/ct2/show/NCT03239808> [accessed 04.08.17].
21. Obi Y, Kalantar-Zadeh K, Streja E, Daugirdas JT. Prediction equation for calculating residual kidney urea clearance using urine collections for different hemodialysis treatment frequencies and interdialytic intervals. *Nephrol Dial Transplant*. 2018;33:530-9, <http://dx.doi.org/10.1093/ndt/gfw473>.
22. Casino F, Basile C. How to set the stage for a full-fledged clinical trial testing 'incremental haemodialysis'. *Nephrol Dial Transplant*. 2018;33:1-8, <http://dx.doi.org/10.1093/ndt/gfx225>, 1003-9.
23. Casino FG, Basile C. A user-friendly tool for incremental haemodialysis prescription. *Nephrol Dial Transplant*. 2018;33:1046-53, <http://dx.doi.org/10.1093/ndt/gfx343>.
24. Daugirdas JT, Depner TA, Greene T, et al. Solute-solver: a web-based tool for modeling urea kinetics for a broad range of hemodialysis schedules in multiple patients. *Am J Kidney Dis*. 2009;54:798-809.
25. Rebollo-Rubio A, Morales-Asencio JM, Pons-Raventos ME, Mansilla-Francisco JM. Grupo de gestión de la calidad de la Sociedad Española de Nefrología. Multicentre study of haemodialysis costs. *Nefrologia*. 2011;31:299-307, <http://dx.doi.org/10.1159/000365819>.
26. National Kidney Foundation NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacy. *Am J Kidney Dis*. 1997;30 Suppl. 2:S67-136.
27. Neri L, Viglino G, Marinangeli G, Rocca AR, Laudon A, Ragusa A, et al., Peritoneal Dialysis Study Group of Italian Society of Nephrology. Incremental start to PD as experienced in Italy: results of censuses carried out from 2005 to 2014. *J Nephrol*. 2017;30:593-9, <http://dx.doi.org/10.1007/s40620-017-0403-0>.
28. Meyer TW, Peattie JW, Miller JD, Dinh DC, Recht NS, Walther JL, et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. *J Am Soc Nephrol*. 2007;18:868-74.
29. Tammy L, Sirich TL, Funk BA, Plummer NS, Hostetter TH, Meyer TW. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. *J Am Soc Nephrol*. 2014;25:615-22.
30. Sirich TL, Fong K, Larive B, et al. Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial. *Kidney Int*. 2017;91:1186-92.
31. González-Sanchidrián S, Deira J, Suárez MA. Progressive hemodialysis: is it the future, or the present? *Semin Dial*. 2017;30:80.
32. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med*. 2002;347:2010-9.
33. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med*. 2010;363:609-19.